RxDoctor Payments Data

Dona Stone, MD

Internal Medicine · Lakeland, FLNPI 1265404404

Payments from drug & device makers

$1,362in general payments, 2019–2025

Across 116 payments — averaging $11.74 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$515
  • Biohaven Pharmaceuticals, Inc.$239
  • Pfizer$217
  • Boehringer Ingelheim$77
  • Amgen$67
  • Dexcom, Inc.$63
  • plus $185 from 7 others

What the payments were for

  • Food & beverage$1,34799%
  • Education$151%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,362 in reported general payments places this provider in the 70th percentile of 8,530 internal medicine providers in Florida.

See all internal medicine providers in Florida

Medicare billing

Part B allowed, 2024
$210,399
Medicare patients
515
Services billed
3,393

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban219$206,116
JardianceEmpagliflozin85$90,387
OzempicSemaglutide59$88,680
MounjaroTirzepatide58$60,913
XareltoRivaroxaban64$48,168
TrulicityDulaglutide32$46,275
JanuviaSitagliptin Phosphate25$22,571
Breo ElliptaFluticasone/Vilanterol29$20,792
Lantus SolostarInsulin Glargine,hum.Rec.Anlog92$17,534
Trelegy ElliptaFluticasone/Umeclidin/Vilanter14$17,138
MyrbetriqMirabegron25$16,679
JanumetSitagliptin Phos/Metformin Hcl12$12,622
ShingrixVaricella-Zoster Ge/As01b/Pf38$8,278
SynthroidLevothyroxine Sodium80$7,779
ArexvyRsvpref3 Antigen/As01e/Pf22$6,775

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis, Paxlovid$217$208,975235 claims
Lilly USA, LLCMounjaro, Trulicity$31$107,18890 claims
Boehringer IngelheimJardiance$77$90,38785 claims
GSKBreo Ellipta, Trelegy Ellipta, Shingrix, Arexvy$14$52,983103 claims
Johnson & JohnsonXarelto$28$48,16864 claims
AbbVieSynthroid, Lexapro$18$13,52893 claims
AstraZenecaSymbicort$515$3,76416 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 8,530 internal medicine providers in Florida.

Other internal medicine in Lakeland

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →